Developer docs
API playgroundTry for free, no card

Search company profiles

Myrexis, Inc.

Full company profile

uuid002i7db

Namestring
Myrexis, Inc.
Legal namestring
Myrexis, Inc.
Websiteurl
myrexis.com
Company typeenum
Private
Founded yearint
1999
Descriptiontext

Myrexis, Inc. is a New York-based life sciences company that suspended all of its preclinical and clinical development programs in oncology and autoimmune diseases in February 2012. Following this suspension, the company ceased active research and product development activities and shifted to evaluating strategic alternatives, with a stated focus on identifying and making financial investments in life sciences assets. The company is no longer developing or commercializing pharmaceutical products and has no disclosed customers, revenue streams, or active partnerships.

The company is managed by a single executive, Jonathan Couchman, who holds the roles of President, CEO, CFO, and Director — a consolidation that reflects the company's minimal operational footprint. Mr. Couchman concurrently serves in the same capacities at Xstelos Holdings, Inc., and the company's registered office is co-located with Couchman Management LLC at 600 Fifth Avenue in New York. Reported financial figures appear anomalous, showing multi-trillion-dollar EBITDA and net loss figures that suggest either data corruption, distressed reporting, or unit-misstated figures rather than meaningful operational performance.

Myrexis currently operates as a shell company in strategic alternatives evaluation mode. There are no active product candidates, no clinical pipeline, no disclosed intellectual property under active development, and no commercial operations. The company's sole forward-looking activity is the evaluation of potential financial investments in external life sciences assets, positioning it as a potential investment vehicle rather than an operating business.

Short descriptiontext

Myrexis, Inc. is a New York-based life sciences company that suspended all preclinical and clinical development programs in oncology and autoimmune diseases in February 2012 and is currently evaluating strategic alternatives focused on financial investments in life sciences assets.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSalt Lake City, United States
HQ citystring
Salt Lake City
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
small molecule therapeutics, oncology drug development, autoimmune disease therapies, life sciences investments, pharmaceutical R&D
Industry4 codes
PRIMARYHLAIAAAC
Oncology & Hematology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAAAD
Immunology & Inflammation Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAB
Immunology & Autoimmune Specialty Pharmaceuticals
SECONDARYHLAIALAE
Clinical Development (Phase I–III Trial Design & Execution)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
NAICS code2 codes
  • Pharmaceutical and Medicine Manufacturing32541
  • Pharmaceutical Preparation Manufacturing325412
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Pharmaceutical Therapeutics
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Financial Investments in Life Sciences
TypeLicensing Royalties
Description

The company is currently focused on identifying, evaluating, and making financial investments in life sciences assets as part of its strategic alternatives evaluation. No active product revenue is being generated from suspended development programs.

myrexis.com
Cost components3 values
Personnel, Operations, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Myrexis, Inc. is a New York-based life sciences company that historically conducted preclinical and clinical development of small molecule therapeutics for oncology and autoimmune diseases. In February 2012, the company suspended all such development programs and is now focused on evaluating strategic alternatives, including identifying, evaluating, and making financial investments in life sciences assets.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Myrexis, Inc. is a life sciences company headquartered in New York that is currently in the process of evaluating strategic alternatives, including identifying and making financial investments in life sciences assets. The company suspended all preclinical and clinical development programs in oncology and autoimmune diseases in February 2012. No active products or services are currently being offered based on the available information.

Scale indicator2 records

Each record includes

Type, Value, Description, Source

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight1 record

Each record includes

Type, Description

Peers8 records
TypeBroad incumbent
Description

Regeneron is a leading biotechnology company with strong franchises in ophthalmology, immunology, and oncology. It is a broad incumbent that competes in the inflammation and oncology therapeutic spaces where Myrexis once operated.

TypeBroad incumbent
Description

AbbVie is a global biopharmaceutical company with a flagship immunology franchise (Humira/Skyrizi/Rinvoq). It is the dominant incumbent in the autoimmune/immunology therapeutic area that was one of Myrexis's two historical focus areas.

TypeDirect peer
Description

Xstelos Holdings is a publicly traded shell/holding company whose President, CEO, CFO and Chairman is Jonathan Couchman — the same individual who leads Myrexis. The two entities share a CEO/CFO and a similar shell structure, making Xstelos the closest structural peer to Myrexis.

TypeBroad incumbent
Description

Pfizer is a leading global pharmaceutical company with major oncology and immunology pipelines. It is a broad incumbent in the same therapeutic categories Myrexis once targeted and would be a logical acquirer of any revived Myrexis assets.

TypeBroad incumbent
Description

Amgen is a major biotechnology company with established franchises in oncology and inflammation/autoimmune diseases, mirroring Myrexis's two historical therapeutic areas. It serves as a broad benchmark for the therapeutic categories Myrexis once operated in.

TypeDirect peer
Description

Pernix Therapeutics was a small specialty pharmaceutical company where Jonathan Couchman previously served on the board. Like Myrexis, it operated in the specialty pharma space with a narrow product portfolio and was subject to strategic restructurings, making it a relevant historical comparison point.

7Bristol-Myers Squibb Company
TypeBroad incumbent
Description

Bristol-Myers Squibb is a major branded pharmaceutical company with significant franchises in oncology and immunology/inflammation — the exact therapeutic categories that Myrexis historically pursued before suspending its programs. It represents the type of large incumbent that would have been a competitor or acquirer in Myrexis's active phase.

TypeEmerging player
Description

Vertex is a specialty biopharmaceutical company focused on small-molecule therapeutics in niche indications — analogous to Myrexis's original model of pursuing smaller-scale drug development in specific disease areas before suspending its programs.

Market position
Strengths3 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat1 record

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights3 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

No data
Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Myrexis, Inc.

Pharmaceutical Therapeuticsmyrexis.com

Myrexis, Inc. is a New York-based life sciences company that suspended all preclinical and clinical development programs in oncology and autoimmune diseases in February 2012 and is currently evaluating strategic alternatives focused on financial investments in life sciences assets.

What Myrexis, Inc. does

Myrexis, Inc. is a New York-based life sciences company that suspended all of its preclinical and clinical development programs in oncology and autoimmune diseases in February 2012. Following this suspension, the company ceased active research and product development activities and shifted to evaluating strategic alternatives, with a stated focus on identifying and making financial investments in life sciences assets. The company is no longer developing or commercializing pharmaceutical products and has no disclosed customers, revenue streams, or active partnerships.

The company is managed by a single executive, Jonathan Couchman, who holds the roles of President, CEO, CFO, and Director — a consolidation that reflects the company's minimal operational footprint. Mr. Couchman concurrently serves in the same capacities at Xstelos Holdings, Inc., and the company's registered office is co-located with Couchman Management LLC at 600 Fifth Avenue in New York. Reported financial figures appear anomalous, showing multi-trillion-dollar EBITDA and net loss figures that suggest either data corruption, distressed reporting, or unit-misstated figures rather than meaningful operational performance.

Myrexis currently operates as a shell company in strategic alternatives evaluation mode. There are no active product candidates, no clinical pipeline, no disclosed intellectual property under active development, and no commercial operations. The company's sole forward-looking activity is the evaluation of potential financial investments in external life sciences assets, positioning it as a potential investment vehicle rather than an operating business.

Myrexis, Inc. firmographics

Firmographics
Name
Myrexis, Inc.
Legal name
Myrexis, Inc.
Website
https://myrexis.com
Company type
Private
Founded year
1999
Operating status
Operating
Headcount range
11–50 employees
Short description
Myrexis, Inc. is a New York-based life sciences company that suspended all preclinical and clinical development programs in oncology and autoimmune diseases in February 2012 and is currently evaluating strategic alternatives focused on financial investments in life sciences assets.
Ownership category
akta.pro rank

Myrexis, Inc. industry classification

Industry
Product category
Pharmaceutical Therapeutics
NAICS
Pharmaceutical and Medicine Manufacturing (32541), Pharmaceutical Preparation Manufacturing (325412)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAAAC
Oncology & Hematology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAAAD
Immunology & Inflammation Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAB
Immunology & Autoimmune Specialty Pharmaceuticals
SECONDARYHLAIALAE
Clinical Development (Phase I–III Trial Design & Execution)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development

Keywords

  • Small molecule therapeutics
  • Oncology drug development
  • Autoimmune disease therapies
  • Life sciences investments
  • Pharmaceutical R&D

Where Myrexis, Inc. is headquartered

Location

Headquarters

HQ city
Salt Lake City
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Myrexis, Inc. business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Operations, Others

Revenue model

  1. Financial Investments in Life Sciences: The company is currently focused on identifying, evaluating, and making financial investments in life sciences assets as part of its strategic alternatives evaluation. No active product revenue is being generated from suspended development programs.

Go-to-market motion1 record

Myrexis, Inc. product offering

Product offering

Core offering

Myrexis, Inc. is a New York-based life sciences company that historically conducted preclinical and clinical development of small molecule therapeutics for oncology and autoimmune diseases. In February 2012, the company suspended all such development programs and is now focused on evaluating strategic alternatives, including identifying, evaluating, and making financial investments in life sciences assets.

Product overview

Myrexis, Inc. is a life sciences company headquartered in New York that is currently in the process of evaluating strategic alternatives, including identifying and making financial investments in life sciences assets. The company suspended all preclinical and clinical development programs in oncology and autoimmune diseases in February 2012. No active products or services are currently being offered based on the available information.

Differentiator

Problem solved

Functional benefit

Myrexis, Inc. technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Myrexis, Inc. partnerships and signals

Strategic signal

Scale indicators2 records

Recent moves5 records

Expansion highlights1 record

Myrexis, Inc. competitors and assessment

Company assessment

Broad incumbents

  • Regeneron Pharmaceuticals, Inc. Regeneron is a leading biotechnology company with strong franchises in ophthalmology, immunology, and oncology. It is a broad incumbent that competes in the inflammation and oncology therapeutic spaces where Myrexis once operated.
  • AbbVie Inc. AbbVie is a global biopharmaceutical company with a flagship immunology franchise (Humira/Skyrizi/Rinvoq). It is the dominant incumbent in the autoimmune/immunology therapeutic area that was one of Myrexis's two historical focus areas.
  • Pfizer Inc. Pfizer is a leading global pharmaceutical company with major oncology and immunology pipelines. It is a broad incumbent in the same therapeutic categories Myrexis once targeted and would be a logical acquirer of any revived Myrexis assets.
  • Amgen Inc. Amgen is a major biotechnology company with established franchises in oncology and inflammation/autoimmune diseases, mirroring Myrexis's two historical therapeutic areas. It serves as a broad benchmark for the therapeutic categories Myrexis once operated in.
  • Bristol-Myers Squibb Company: Bristol-Myers Squibb is a major branded pharmaceutical company with significant franchises in oncology and immunology/inflammation — the exact therapeutic categories that Myrexis historically pursued before suspending its programs. It represents the type of large incumbent that would have been a competitor or acquirer in Myrexis's active phase.

Direct peers

  • Xstelos Holdings, Inc. Xstelos Holdings is a publicly traded shell/holding company whose President, CEO, CFO and Chairman is Jonathan Couchman — the same individual who leads Myrexis. The two entities share a CEO/CFO and a similar shell structure, making Xstelos the closest structural peer to Myrexis.
  • Pernix Therapeutics Holdings, Inc. Pernix Therapeutics was a small specialty pharmaceutical company where Jonathan Couchman previously served on the board. Like Myrexis, it operated in the specialty pharma space with a narrow product portfolio and was subject to strategic restructurings, making it a relevant historical comparison point.

Emerging players

  • Vertex Pharmaceuticals Incorporated: Vertex is a specialty biopharmaceutical company focused on small-molecule therapeutics in niche indications — analogous to Myrexis's original model of pursuing smaller-scale drug development in specific disease areas before suspending its programs.

Market position

Strengths3 records

Weaknesses4 records

Competitive moat1 record

Key risks5 records

Key highlights3 records

Customer concentration

Myrexis, Inc. social profiles

Digital presence

Myrexis, Inc. financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Myrexis, Inc. leadership team

Management profile

Number of profiles

Profiles1 record

Myrexis, Inc. funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Myrexis, Inc. M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Myrexis, Inc.

What does Myrexis, Inc. do?

Myrexis, Inc. is a New York-based life sciences company that historically conducted preclinical and clinical development of small molecule therapeutics for oncology and autoimmune diseases. In February 2012, the company suspended all such development programs and is now focused on evaluating strategic alternatives, including identifying, evaluating, and making financial investments in life sciences assets.

When was Myrexis, Inc. founded?

Myrexis, Inc. was founded in 1999. It employs 11 to 50 people.

Where is Myrexis, Inc. based?

Myrexis, Inc. is headquartered in Salt Lake City, United States, in the North America region.

How does Myrexis, Inc. make money?

One revenue line is on record: financial Investments in Life Sciences.

Who are Myrexis, Inc.'s main competitors?

Broad incumbents on record are Regeneron Pharmaceuticals, Inc., AbbVie Inc., Pfizer Inc., Amgen Inc. and Bristol-Myers Squibb Company. Direct peers are Xstelos Holdings, Inc. and Pernix Therapeutics Holdings, Inc.. Vertex Pharmaceuticals Incorporated is listed as an emerging player.

Does Myrexis, Inc. have an API?

No public API is recorded for Myrexis, Inc..

What industry is Myrexis, Inc. in?

Myrexis, Inc.'s product category is Pharmaceutical Therapeutics. Its primary akta.pro industry code is HLAIAAAC, Oncology & Hematology Pharmaceuticals, with a secondary code of HLAIAAAD, Immunology & Inflammation Pharmaceuticals. Its NAICS code is 32541 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireGlobal Vascular Disrupting Agents Market Report 2021-2030 with Company Profiles of AGC Biologics, Avid Bioservices, Bionomics, Mateon Therapeutics, Myrexis, VBL TherapeuticsResearch and Markets has published a comprehensive market report on Vascular Disrupting Agents (VDAs) covering the period 2021-2030, analyzing the current and future potential of these cancer treatment candidates being developed by multiple pharmaceutical companies. The report profiles key players including AGC Biologics, Avid Bioservices, Bionomics, Mateon Therapeutics, Myrexis, and VBL Therapeutics, and features detailed analyses of clinical trials, academic grants, publications, and market opportunity. The niche but emerging field is supported by significant R&D investment, including $95 million in NIH research grants since 2016, with industry analysts projecting healthy growth driven by encouraging clinical research and combination therapy potential.GlobeNewswireDelisting of Securities of LodgeNet Interactive Corporation, Myrexis, Inc., Globalstar, Inc., and School Specialty, Inc. From The NASDAQ Stock MarketNASDAQ announced delisting of LodgeNet Interactive, Myrexis, Globalstar, and School Specialty, all of which had suspended stocks and no trading since suspension dates. NASDAQ will file Form 25 with the SEC, and delistings take effect ten days after filing.GlobeNewswireMyrexis, Inc. Announces the Cancellation of Its Upcoming Shareholder MeetingMyrexis, Inc. cancelled its Jan. 23 shareholder meeting and instead declared a $2.86 per share special cash distribution, payable to shareholders of record on Feb. 4, 2013. The board also appointed Jonathan M. Couchman as director, president, and CEO, and the company will continue evaluating strategic alternatives.GlobeNewswireMyrexis, Inc. Announces Board Approval of Plan of Complete Liquidation and DissolutionMyrexis, Inc. announced its board approved a plan to dissolve and liquidate, subject to shareholder approval. The company estimates an initial liquidating distribution of $72.9 million to $77.9 million, or $2.72 to $2.91 per share, after reserving $7 million to $12 million for liabilities. Shareholders will vote on the plan via proxy materials.GlobeNewswireCORRECTION -- Myrexis to Hold Conference Call to Discuss First Quarter 2012 Financial ResultsMyrexis, Inc. issued a correction notice stating its conference call to discuss first quarter 2012 financial results will be held on Wednesday, November 9, 2011. The notice confirms all other information in the original press release remains accurate.GlobeNewswireMyrexis to Present at 10th Annual Needham Healthcare ConferenceMyrexis, Inc. announced that CEO Adrian Hobden will present an overview of the company at the 10th Annual Needham Healthcare Conference on April 5-6, 2011 in New York City. The presentation will be audio webcast live and archived for 90 days. The company's oncology pipeline includes Azixa in Phase 2 clinical development.GlobeNewswireMyriad Pharmaceuticals Formally Adopts Its Name Change to Myrexis, Inc. Effective July 1, 2010Myriad Pharmaceuticals will change its name to Myrexis, Inc. effective July 1, 2010, after shareholder approval. The company, spun out of Myriad Genetics, focuses on oncology with three drug candidates, including Azixa in Phase 2 trials. It expects to report advances on MPC-3100 and MPC-9528 in the second half of 2010.